Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors
January 23 2020 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced the
appointment of Robert Iannone, M.D., M.S.C.E., to its board of
directors.
“Rob brings enormous value to the Jounce board of directors as
we move further into the clinic and continue to broaden our
pipeline of discovery programs,” said Richard Murray, Ph.D., chief
executive officer and president of Jounce Therapeutics. “With his
depth of immuno-oncology expertise and clinical development
experience, we believe that his insights will be unparalleled as we
work to execute on our mission of transforming the way cancer is
treated.”
Dr. Iannone serves as the executive vice president, research and
development of Jazz Pharmaceuticals, which he joined in May 2019.
Previously, he served as the chief medical officer and head of
research and development of Immunomedics and has also held several
leadership roles at AstraZeneca and Merck. At AstraZeneca, he was
senior vice president and head of immuno-oncology, global medicines
development. At Merck, Dr. Iannone served in various roles,
culminating in his eventual role as executive director and section
head of oncology clinical development. Dr. Iannone holds a B.S.
from The Catholic University of America, an M.D. from Yale
University and an M.S.C.E. from University of Pennsylvania.
He completed his residency in Pediatrics and fellowship in
Pediatric Hematology-Oncology at Johns Hopkins University.
“I am honored to join the Jounce board of directors and to work
alongside this team of cancer therapy experts. Jounce’s
multi-faceted approach to cancer treatment, particularly its
prioritization of novel targets and related biomarkers as a way to
address current challenges in immuno-oncology is differentiated,
timely and exciting,” said Dr. Iannone. “I look forward to working
with the board and management team during this time in the
company’s development.”
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
has three development stage programs, two of which are
clinical-stage programs, vopratelimab, a monoclonal antibody that
binds to and activates ICOS, and JTX-4014, a PD-1 inhibitor
intended for potential combination use with Jounce’s broader
pipeline. Vopratelimab is currently being assessed in a Phase 2
clinical trial and JTX-4014 Phase 1 data were reported in November
2019 with additional studies planned. The next development
candidate to emerge from Jounce’s Translational Science Platform is
JTX-1811, a monoclonal antibody designed to deplete T regulatory
cells in the tumor microenvironment. JTX-1811 is currently in
IND-enabling activities. In addition, Jounce has exclusively
licensed worldwide rights to JTX-8064, a LILRB2 receptor
antagonist, to Celgene. For more information, please visit
www.jouncetx.com.
Investor and Media Contact:Komal JoshiJounce
Therapeutics, Inc.(857) 320-2523kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024